...- Patients must have FLT3 mutated AML, either ITD or kinase domain mutations...

...Cytoreductive therapy with hydroxyurea is recommended if WBC is > 50.000/µl, but should cease at least one day prior to starting study medication• Patient age equal or of greater than 60 years• Patients must have FLT3 mutated AML, either ITD or kinase domain mutations• ECOG Performance score 3 or less (Karnofsky Performance Score >40%).• Life expectancy more than four weeks.• Adequate hepatic and renal function, as defined by serum transaminases <2.5x ULN, bilirubin <1.5x ULN. ...

...potent inhibitory activity of sorafenib and sunitinib was observed against FLT3 (IC50s of 4 and 12 nmol/L, respectively) and PDGFRα (0.5 and 3 nmol/L), neither compound exhibited high potency against KIT (59 and 56 nmol/L) or FGFR1 (>100 and >100 nmol/L; ref. Fig. 2B and Table 1).

...we tested the effect of combining the FLT3 inhibitor SU11248 with cytarabine or daunorubicin on the proliferation and survival of cell lines expressing either mutant (FLT3 ITD or FLT3 D835V) or wild-type (WT) FLT3. SU11248 had additive-to-synergistic inhibitory effects on FLT3-dependent leukemic cell proliferation when combined with cytarabine or daunorubicin...Combining SU11248 and cytarabine synergistically inhibited the proliferation of primary AML myeloblasts expressing FLT3 ITD but not WT FLT3 protein.